ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: Pasireotide Works Well In Acromegaly Trial

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company said Monday. Patients treated with pasireotide LAR, or SOM230, were 63% more likely to achieve control of their disease than those treated with Novartis' Sandostatin LAR, or octreotide, the study showed. The safety profile of pasireotide LAR was similar to that of octreotide LAR, known under the brand name Sandostatin, with the exception of a higher degree of hyperglycemia, Novartis said. "The positive results seen in the Phase III trial point to the potential role of pasireotide LAR in treating patients with acromegaly, a condition for which there remains an unmet need," said Herve Hoppenot, president of Novartis Oncology, in a statement. "These findings are welcome news as we continue our research efforts to discover treatments for patients with pituitary-related conditions." Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in enlarged hands, feet and internal organs, and increased risk of death. Novartis said the data were presented at the 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting in Florence, Italy. The medical meeting runs from May 5 to May 9. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043;

Stock News for Novartis (NVS)
11/25/201511:30:00Prescription Skin Drugs Explode in Costs, Study Shows
11/23/201509:20:02The FDA Approves Exelixis, Inc's New Cancer Drug
11/23/201508:46:033 Dividend Stocks You Don't Have to Babysit
11/20/201517:35:00Novartis Finalizes Settlement With Justice Department
11/20/201508:41:03How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust
11/19/201509:16:045 Things GlaxoSmithKline PLC Wants You to Know
11/17/201511:40:56Why Ophthotech Corporation's Shares Soared in October
11/07/201513:40:09Momenta Slowed (Temporarily)
11/06/201512:16:03Why XOMA Shares Are Crashing
11/04/201510:20:02Is This Drug Going to Be a Big Threat to Biogen and Novartis...
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/31/201509:21:03Generic Copaxone Isn't Derailing Teva Pharmaceuticals...Yet
10/29/201516:07:02GlaxoSmithKline's Diverging Q3 Results Imply a Long Road to Recovery
10/28/201509:20:00GlaxoSmithKline Sees Higher Sales
10/28/201509:03:00GlaxoSmithKline Sees Higher Sales in Third Quarter But Lower...
10/27/201511:15:00Novartis Profit Hurt by U.S. Settlement -- 4th Update
10/27/201507:49:00Novartis Profit Hurt by U.S. Settlement-- Third Update
10/27/201505:50:00Global Stocks Fall Ahead of Fed Meeting
10/27/201505:05:00Novartis Profit Hurt by U.S. Settlement -- 2nd Update
10/27/201504:57:00Novartis Profit Hurt by U.S. Settlement -- Update

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations